NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

Rhea-AI Summary

NorthStrive Biosciences (NASDAQ: ELAB) announced a third amendment to its License Agreement with MOA Life Plus (KOSDAQ: 142760) covering dual myostatin assets EL-32 and EL-22.

The Amendment updates the timing and key development milestones for human clinical programs, aligning schedules with both parties' R&D and regulatory expectations and reinforcing disciplined development planning for the human health portfolio.

Key Figures

License amendment number: Third amendment

1 metrics

License amendment number Third amendment Amendment to existing EL-22/EL-32 License Agreement with MOA Life Plus

Market Reality Check

Price: $1.6700 Vol: Volume 282,417 is below t...

low vol

$1.6700 Last Close

Volume Volume 282,417 is below the 20-day average of 1,106,516 (about 0.26x typical activity), suggesting a relatively muted trading response ahead of this amendment. low

Technical Shares at $1.87 sit far below the $105.62 200-day MA and 99.6% under the $466.20 52-week high, despite being just above the $1.70 52-week low.

Peers on Argus

Scanner data flags peers SPRC and INDP moving up, while other biotech peers show...

2 Up

Scanner data flags peers SPRC and INDP moving up, while other biotech peers show mixed performance. With ELAB up about 2.75% and sector_momentum marked false, today’s move appears more company-specific than part of a broad biotechnology rotation.

Historical Context

5 past events · Latest: Mar 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	Defense registration	Positive	-22.5%	SVM Machining secured ITAR registration to pursue defense contracts.
Mar 10	Preclinical study start	Positive	+3.7%	NorthStrive began an EL-32 preclinical study for GLP-1 weight loss therapy.
Mar 04	Reverse stock split	Negative	-32.8%	Announced 1-for-6 reverse split and resulting share count changes.
Feb 19	Patent filings	Positive	+17.9%	Filed 10 U.S. patents extending EL-22/EL-32 into animal health uses.
Feb 11	License agreement	Positive	-0.6%	Signed exclusive license for EL-22/EL-32 commercialization in animal health.

Pattern Detected

Recent ELAB news often triggers sharp but inconsistent reactions: positive operational updates around EL-22/EL-32 and patents have seen gains, while corporate or capital-structure items like the reverse split have drawn sizeable selloffs.

Recent Company History

Over the last few months, PMGC/ELAB has balanced biotech development with capital and corporate actions. In February–March 2026, NorthStrive advanced EL-22/EL-32 through a license deal, patent filings, and an EL-32 preclinical study, with several of these updates producing positive one-day moves. By contrast, the 1-for-6 reverse split on March 10, 2026 and some operational milestones, like ITAR registration at SVM, coincided with notable downside, underscoring volatile sentiment around the broader strategy.

Market Pulse Summary

This announcement refines timelines and milestones for EL-22 and EL-32 human development under the M...

Analysis

This announcement refines timelines and milestones for EL-22 and EL-32 human development under the MOA Life Plus license, signaling ongoing commitment to the myostatin-based platform alongside GLP-1 therapies. Placed in context of recent preclinical work, patent activity, and a reverse split, investors may track how consistently management executes against these updated clinical and regulatory goals, as well as any further financing structures tied to progressing the human health portfolio.

Key Terms

license agreement, myostatin, glp-1

3 terms

license agreement regulatory

"announced today a third amendment (“Amendment”) to its existing License Agreement"

A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.

myostatin medical

"for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1"

Myostatin is a naturally occurring protein produced by muscle that acts like a brake, limiting how big and strong muscles can grow. Because medicines that block myostatin can allow muscles to increase in size and strength, investors follow related drug programs closely for their potential to treat muscle-wasting diseases and age-related weakness; trial results, safety and regulatory approval prospects can materially affect a company’s value.

glp-1 medical

"Targeting Muscle Preservation in Combination with GLP-1 Treatments"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

AI-generated analysis. Not financial advice.

NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.’s (NASDAQ: ELAB) (“PMGC,” “we,” or “our”) wholly owned subsidiary, NorthStrive Biosciences Inc. (“Northstrive Biosciences”), announced today a third amendment (“Amendment”) to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company (“MOA,” and such existing agreement, as amended, “License Agreement”) Northstrive Biosciences holds for EL-32 and EL-22.

The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties’ research and development and regulatory expectations.

Northstrive Biosciences believes the Amendment reinforces the company’s commitment to disciplined development planning and the continued progression of its human health portfolio.

About MOA Life Plus Co. Ltd. [KOSDAQ: 142760]

MOA Life Plus Co. Ltd.is a Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies. MOA partners globally to advance scientific innovation across human and animal health applications.

About NorthStrive Biosciences Inc.

NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:

IR@pmgcholdings.com

FAQ

What did NorthStrive Biosciences announce on March 27, 2026 regarding ELAB and MOA Life Plus?

NorthStrive Biosciences announced a third amendment to its license with MOA Life Plus for EL-32 and EL-22 clinical programs. According to the company, the Amendment updates timing and development milestones to align R&D and regulatory expectations.

How does the March 27, 2026 amendment affect EL-32 and EL-22 clinical development timelines for ELAB?

The amendment updates the timing and key milestones for EL-32 and EL-22 human clinical programs. According to the company, schedules were aligned to reflect joint R&D and regulatory expectations without disclosing specific dates.

Does the ELAB licensing amendment with MOA change ownership or rights for EL-32 and EL-22?

The Amendment modifies the existing License Agreement but does not state changes in ownership or license rights. According to the company, the update focuses on development timing and milestone alignment between the parties.

What is the strategic purpose of ELAB's March 27, 2026 amendment with MOA for myostatin assets?

The strategic purpose is to align clinical development schedules and regulatory planning for EL-32 and EL-22. According to the company, the Amendment reinforces disciplined development planning and continued progression of its human health portfolio.

Will the ELAB and MOA amendment accelerate clinical trials for EL-32 or EL-22?

The Amendment updates timing and milestones but does not claim acceleration of trials. According to the company, the change aligns schedules with joint R&D and regulatory expectations; no specific acceleration or dates were provided.